Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.
- DOI
- 10.3389/fonc.2026.1851781
- Published
- 2026
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2026.1851781,
title = {Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.},
author = {Al-Asa'd Y and Qasem N and Alshurafa A and Al-Farsi K and Yassin MA},
year = {2026},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2026.1851781},
url = {https://doi.org/10.3389/fonc.2026.1851781}
}RIS
TY - JOUR TI - Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review. AU - Al-Asa'd Y AU - Qasem N AU - Alshurafa A AU - Al-Farsi K AU - Yassin MA PY - 2026 JO - Frontiers in oncology DO - 10.3389/fonc.2026.1851781 UR - https://doi.org/10.3389/fonc.2026.1851781 ER -
APA
Y, A., N, Q., A, A., K, A., & MA, Y. (2026). Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1851781
Source records
- pubmed · retrieved 2026-09-26T13:29:19.183Z